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Abstract
Objective: Insulin-like growth factor-I (IGF-I) has been suggested to be a prognostic marker for the
development of cancer and, more recently, cardiovascular disease. These diseases are closely linked
to obesity, but reports of the association of IGF-I with measures of obesity are divergent. In this
study, we assessed the association of age-dependent IGF-I standard deviation scores with body
mass index (BMI) and intra-abdominal fat accumulation in a large population.
Design: A cross-sectional, epidemiological study.
Methods: IGF-I levels were measured with an automated chemiluminescence assay system in 6282
patients from the DETECT study. Weight, height, and waist and hip circumference were measured
according to the written instructions. Standard deviation scores (SDS), correcting IGF-I levels for
age, were calculated and were used for further analyses.
Results: An inverse U-shaped association of IGF-I SDS with BMI, waist circumference, and the ratio of
waist circumference to height was found. BMI was positively associated with IGF-I SDS in normal
weight subjects, and negatively associated in obese subjects. The highest mean IGF-I SDS were
seen at a BMI of 22.5–25 kg/m2 in men (þ0.08), and at a BMI of 27.5–30 kg/m2 in women
(þ0.21). Multiple linear regression models, controlling for different diseases, medications and risk
conditions, revealed a significant negative association of BMI with IGF-I SDS. BMI contributed
most to the additional explained variance to the other health conditions.
Conclusions: IGF-I standard deviation scores are decreased in obesity and underweight subjects. These
interactions should be taken into account when analyzing the association of IGF-I with diseases and
risk conditions.
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Introduction
Insulin-like growth factor-I (IGF-I) plays a major role in
regulating cell growth and differentiation and is a
major mediator of the various effects of growth hor-
mone (GH). In consequence, serum levels of IGF-I are
often used to assess the status of the GH axis (1–4)
and, in consequence, IGF-I has been established as a
useful marker for monitoring GH substitution in GH-
deficient states (5) and for monitoring treatment effects
in acromegaly (4).
In addition to these well established applications, sev-
eral recent studies have provided evidence that IGF-I
levels are positively associated with the risk for certain
malignancies (6, 7) and negatively associated with car-
diovascular risk factors and diseases (8–11). Although
the relationship between IGF-I and cardiovascular dis-
ease remains inconclusive, with other studies showing
detrimental effects of IGF-I on cardiovascular risk
(12 –14), these data clearly demonstrate that IGF-I is
no longer a marker exclusively used for the diagnosis
and follow-up of patients with disorders of GH
secretion, but is of interest in many other diseases
such as malignancies and cardiovascular disorders.
Since obesity is often causally involved in the patho-
genesis of these diseases, it is crucial to characterize
precisely a possible association of IGF-I levels with
nutritional status before discussing a causal link
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between IGF-I and various disease states. In conditions
of underweight such as anorexia nervosa or cachexia,
decreased IGF-I and increased GH levels due to GH
insensitivity are found (15–18). Obesity is character-
ized by blunted GH secretion (16, 19) but reports of
IGF-I levels in obese subjects are divergent. Some
authors have reported decreased levels of IGF-I
(20–22), while others have found normal levels
(23–25), which could be due to an increased GH sen-
sitivity in obese subjects (25). Negative correlations of
IGF-I levels to visceral fat areas, assessed by computed
tomography scan (23, 26, 27) have been reported
even in the absence of significant correlations between
body mass index (BMI) and IGF-I (23), suggesting that
the amount of visceral fat is an important determinant
of IGF-I levels.
Since all available studies about the association
between obesity and IGF-I levels have been conducted
in small populations, the present study aimed to assess
this question in a population of more than 6000 subjects
participating in the DETECT study, a large multistage
cross-sectional study in Germany. To minimize the
influence of age, IGF-I levels were measured with an
automated immunoassay system, for which recent age-
dependent reference values in a large cohort of normal-
weight healthy subjects have been published (29), and
were expressed as standard deviation scores (SDS).
Subjects and methods
Subjects
The study was approved by the local ethics committee
and all patients gave written informed consent. IGF-I
was measured in 3723 women and 2559 men, a
random sample from the DETECT study, representative
of the total DETECT population.
DETECT is a large multistage cross-sectional study of
55 518 unselected consecutive patients (59% women
and 41% men; over 17 years of age) in 3188 primary
care offices in Germany, with a prospective 12-month
component in a random subset of 7519 patients, charac-
terized additionally by an extensive standardized labora-
tory program with focus on cardiovascular (CV) risk
assessment. Patients’ self-assessments and physicians’
assessments of each patient were obtained. Table 1 sum-
marizes the patients’ characteristics in detail. Further
details are available at http://www.detect-studie.de.
The design, methods and baseline characteristics of
DETECT, and first prevalence data have been published
by Wittchen et al. (30).
Instruments and measurements
Physicians’ diagnoses were classified as definite, poss-
ible or not present, and current medication was
recorded. In the case of diabetes, type 1 or type 2 was
indicated. Laboratory values, obtained in the central
laboratory in Graz, were additionally used for the
diagnosis of dyslipidemia. Doctors were advised to
measure weight, height, blood pressure, and waist
and hip circumference according to the manual
instructions. Systolic and diastolic blood pressures
were measured by indirect cuff sphygmomanometry
after several minutes of rest in the sitting position.
Waist circumference (WC) was measured with a tape
measure midway between the lowest rib and the
pelvis; hip circumference (HC) was measured at the
widest circumference of the hip. The following anthro-
pometric parameters were calculated: BMI, WC (in cm),
HC (in cm), waist-to-hip ratio (WHR) (WC divided by
the HC), waist-to-tallness-ratio (WTR) (WC divided by
measured height in cm).
For the assessment of confounding conditions, phys-
icians’ diagnoses were used except for the following:
dyslipidemia (levels of total cholesterol .6.2 mmol/l
(240 mg/dl), low density lipoprotein-cholesterol
.4.1 mmol/l (160 mg/dl) or high density lipoprotein-
cholesterol ,1.0 mmol/l (40 mg/dl)) and hypertension
(systolic blood pressure (SBP) $140 mmHg or diastolic
blood pressure (DBP) . ¼ 90 mmHg or intake of anti-
hypertensive medication (NHANES criteria)).
IGF-I measurements
Blood samples were collected and shipped by courier
within 24 h to the central laboratory at the Medical
University of Graz (Austria). IGF-I was measured with
an automated chemiluminescence system (Nichols
Advantage, Bad Vilbel, Germany). The maximal intra-
and interassay coefficients of variation were 5% and
7% respectively. Reagents and secondary standards
were used as recommended by the manufacturer.
IGF-I levels were transformed to age-dependent IGF-I
SDS according to Brabant et al. (29).
Table 1 Patients characteristics.
Female (n ¼ 4438) Male (n ¼ 3081)
% %
Sex 59.0 41.0
Age (mean/S.D.) 57.0/14.9 58.7/13.5
BMI (mean/S.D.) 26.7/5.3 27.7/4.2
Diabetes type 2a 17.3 27.4
Kidney diseases 2.9 5.9
Liver diseases 5.7 6.7
Cancer 3.2 3.6
CHDb 9.7 20.6
Hypertensionc 55.9 67.0
Dyslipidemiad 57.8 71.9
Fibrate intake 1.1 2.7
HRTe 12.8 —
aClinical diagnosis of type 2 diabetes; bclinical diagnosis of CHD, coronary
heart disease; csystolic blood pressure (SBP) . ¼ 140 mmHg or diastolic
blood pressure (DBP) . ¼ 90 mmHg or intake of antihypertensive medi-
cation (NHANES criteria); dlevels above total cholesterol .240 mg/dl, LDL-
cholesterol .160 mg/dl or HDL cholesterol ,40 mg/dl; ehormone replace-
ment therapy for women.
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Statistical analyses
BMI dependent IGF-I SDS means and standard
deviations were illustrated with fractional polynomial
fit after smoothing the means and standard deviations
in each BMI class using the smoothing window
BMI 2 1 to BMI þ 1. Multiple linear regression
models were used to assess the influence of different
nutritional parameters on IGF-I SDS, controlling for
different diseases and risk conditions. Model fits were
tested using the Pregibon link test. To account for
the stratified sampling design, we calculated confidence
intervals with the Huber-White sandwich method. The
difference between the model proposed by Brabant et al.
(29) and the model estimated in our sample was tested
with a t-test, using the normality of regression coeffi-
cients. We also used a t-test for comparison of the
IGF-I SDS levels in different age groups. All statistical
analyses were conducted with the software package
STATA 8 (Stata Statistical Software: Release 9.0.
College Station, TX: Stata Corporation, 2005).
Results
There were no differences in IGF-I, BMI, or age among
those who were fasted and the non-fasted subjects. We
estimated the linear regression model used for calcu-
lation of the IGF-I SDS proposed by Brabant et al. (29)
in our sample. Our model differed significantly
(P , 0.001) from that of Brabant et al. The IGF-I SDS
mean in our sample was 0.08 (P , 0.001) and 0.08
(P , 0.001) after exclusion of subjects with a BMI
.30 and ,18. Lower IGF-I SDS values (P , 0.001)
were found in younger (mean ¼ 20.15, 18–44
years) age groups and higher values (P , 0.001) in
older age groups (mean ¼ 0.34, 66 þ years). The
means of patients aged 45–65 years were not different
to zero. Therefore, we additionally adjusted for age in
our regression analysis. IGF-I SDS were calculated in
different BMI groups with a width of 2.5 starting
from #17.5 kg/m2 as shown in Table 2. In the total
sample, IGF-I SDS increased with increasing BMI
groups up to a BMI of 27.5–30 kg/m2 in women and
Table 2 IGF-I SDS in BMI, WTR, and WC groups.
Total groupa
Subjects with diabetes, cancer, kidney, liver
diseases or HRT excluded
Female (n ¼ 3723) Male (n ¼ 2559) Female (n ¼ 2377) Male (n ¼ 1606)
n Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D.
BMI , ¼ 17.5 17 20.33* 0.49 3 20.18 0.65 16 20.36* 0.5 2 20.43 0.69
17.5 , BMI , ¼ 20 195 20.07* 0.86 15 20.67* 0.76 162 20.09* 0.82 13 20.70* 0.82
20 , BMI , ¼ 22.5 593 0.06* 0.82 136 20.14* 0.88 458 0.04* 0.82 104 20.13 0.89
22.5 , BMI , ¼ 25 780 0.15 0.84 531 0.08 0.93 536 0.09 0.8 382 0.05 0.85
25 , BMI , ¼ 27.5 707 0.18 0.91 719 20.01 0.89 438 0.14 0.87 488 0.02 0.87
27.5 , BMI , ¼ 30 551 0.21 0.92 539 20.07* 0.89 321 0.19 0.79 316 20.07 0.86
30 , BMI , ¼ 32.5 390 0.13 0.86 317 20.13* 0.88 189 0.11 0.82 170 20.08 0.83
32.5 , BMI , ¼ 35 234 0.02* 0.81 164 20.2* 0.99 124 20.04* 0.82 72 20.18 1.07
35 , BMI , ¼ 37.5 125 20.06* 0.90 69 20.34* 1.05 71 20.16* 0.69 29 0.08 1.07
37.5 , BMI , ¼ 40 59 20.24* 0.81 30 20.05 0.89 27 20.17* 0.73 15 0.07 0.66
BMI . 40 72 20.5* 0.77 36 20.53* 1.17 35 20.41* 0.69 15 20.76* 0.84
WTR , ¼ 0.25 1 1.88 — — — — — — — — — —
0.25 , WTR , ¼ 0.35 3 0.37 0.22 1 20.74 — 3 0.37* 0.22 1 20.74 —
0.35 , WTR , ¼ 0.45 523 20.13* 0.73 82 0.00 0.76 438 20.13* 0.74 69 0.01 0.78
0.45 , WTR , ¼ 0.55 1404 0.15 0.90 842 20.02 0.88 961 0.10 0.84 649 20.03 0.85
0.55 , WTR , ¼ 0.65 1246 0.18 0.87 1250 20.04 0.91 709 0.15 0.83 729 20.03 0.88
0.65 , WTR , ¼ 0.75 460 0.06* 0.89 330 20.20 1.02 226 0.08 0.83 137 20.07 1.00
0.75 , WTR , ¼ 0.85 73 20.21* 0.78 46 20.11 1.05 34 20.30 0.69* 19 20.06 1.02
0.85 , WTR , ¼ 0.95 13 20.40* 0.69 6 20.41* 1.57 6 20.39 0.56* 1 21.67 —
WTR . 0.95 — — — 2 21.33 0.64 — — — 1 20.88 —
WC , ¼ 50 1 1.88 — — — — — — — — — —
50 , WC , ¼ 60 17 20.04 0.65 1 20.74 — 14 20.04 0.71 1 20.74 —
60 , WC , ¼ 70 263 20.16* 0.74 18 20.54* 1.03 223 20.15* 0.75 13 20.72* 1.14
70 , WC , ¼ 80 762 0.06* 0.82 72 0.01 0.78 560 0.01* 0.79 61 0.06 0.8
80 , WC , ¼ 90 994 0.19 0.89 319 20.04 0.83 666 0.17 0.83 252 20.05 0.83
90 , WC , ¼ 100 832 0.16 0.88 890 0.03 0.92 480 0.12 0.83 618 20.01 0.88
100 , WC , ¼ 110 549 0.14 0.9 719 20.07* 0.88 280 0.08 0.86 418 20.01 0.82
110 , WC , ¼ 120 201 0.02* 0.88 358 20.18* 0.97 109 0.00* 0.81 171 20.11 1
120 , WC , ¼ 130 76 20.28* 0.79 125 20.11 1.03 32 20.22* 0.6 52 0.00 0.99
130 , WC , ¼ 140 22 20.38* 0.8 38 20.41* 1.19 10 20.33* 0.69 12 20.24 0.79
WC . 140 6 20.54* 0.77 19 20.23 1.34 3 20.96* 0.87 8 20.22 1.29
a n ¼ 6282 valid observations with measured IGF-I and anthropometric parameters.
* Significantly different (P , 0.05) from group with highest IGF-I SDS mean (reference group marked in bold), tested by multiple t-test.
IGF-I and BMI 701EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006) 154
www.eje-online.org
22.5–25 kg/m2 in men, and then decreased with
further BMI increments. The maximum mean IGF-I
SDS values were 0.21 and 0.08 in women and men
respectively. When subjects with diabetes, cancer,
renal or liver diseases or hormone replacement therapy
were excluded, the results were very similar, with IGF-I
SDS somewhat lower than in the total population. In
this subset of 3983 subjects, peak mean IGF-I SDS
values were 0.19 in women (BMI 27.5–30 kg/m2)
and 0.05 in men (22.5 –25 kg/m2). In men, high
mean IGF-I scores of 0.08 and 0.07 were also found
in the BMI groups of 35–37.5 kg/m2 and 37.5–
40 kg/m2, which may be influenced by the small
number of subjects included in these groups.
Figure 1 shows the blotted IGF-I SDS in the total
sample and after exclusion of subjects with diabetes,
cancer, and kidney or liver diseases. Mean values and
1st and 2nd SDS are shown as smoothed lines.
Table 2 also shows the means and standard deviations
of IGF-I SDS among groups with different WC and WTR.
Again, IGF-I SDS increased in the lower WC and WTR
groups up to a maximum at a WC between 80 and
90 cm and a WTR between 0.55 and 0.65 for females
and at a WC between 90 and 100 cm and a WTR
between 0.35 and 0.45 for males, and then decreased
with higher WC and WTR values.
To calculate which anthropometric parameter con-
tributed most to explained variance (R2) of IGF-I SDS,
we carried out linear regression analyses with each
nutritional parameter. As several conditions could poss-
ibly influence IGF-I SDS, we controlled for cancer, cor-
onary artery disease, diabetes, hypertension,
dyslipidemia, liver diseases, renal diseases, age, and
intake of fibrates or sex hormone replacement therapy
(HRT, in women). The results are shown in Table 3.
There was a weak negative association (indicated by a
negative b-S.D.; an increase of one S.D. of the nutritional
parameter leads to the indicated increase change of
IGF-I SDS) of IGF-I SDS with BMI and other nutritional,
anthropometric parameters in both men and women.
BMI contributed most to the additional explained var-
iance in the other health conditions.
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Figure 1 IGF-I SDS blotted over BMI with smoothed lines indicating mean values and 1st and 2nd S.D. (Left panels) Total sample:
upper panel, women; lower panel, men. (Right panels) Subjects with diabetes, cancer, kidney or liver diseases, or hormone replace-
ment therapy excluded: upper panel, women; lower panel, men.
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Table 3 IGF-I SDS: additional explained variance of nutritional parameters (model 2) to explained variance by the following conditions: diabetes, liver diseases, kidney diseases,
CAD, cancer, hypertension, dyslipidemia, fibrate intake, HRT, and age (model 1). R2: explained variance. Beta S.D.: standardized regression coefficient. Increase of nutritional
parameter for one SD leads to the indicated change of IGF-I SDS.
Model 1a Model 2b
BMI WC HC WHR WTR
R2 R2
Beta-
S.D. CI (95%) R2
Beta-
S.D. CI (95%) R2
Beta-
S.D. CI (95%) R2
Beta-
S.D. CI (95%) R2
Beta-
S.D. CI (95%)
Total
Female 8.03 8.91 20.07 20.098 20.049 8.58 20.07 20.093 20.037 8.4 20.05 20.072 20.023 8.05 20.01 20.042 20.01 8.65 20.07 20.092 20.039
Female, 18–44 years 1.32 2.01 20.06 20.112 20.015 1.6 20.05 20.102 20.012 1.7 20.05 20.093 20.001 1.29 0.00 20.051 20.052 1.68 20.05 20.102 20.006
Female, 45–65 years 4.63 5.2 20.06 20.094 20.021 5.09 20.06 20.099 20.016 4.92 20.04 20.076 20.004 4.67 20.01 20.052 20.023 5.19 20.06 20.1 20.02
Female, 65 þ years 4.25 5.33 20.08 20.132 20.037 4.92 20.07 20.127 20.021 4.55 20.05 20.094 20.003 4.3 20.03 20.077 20.022 4.99 20.07 20.12 20.022
Male 3.26 3.95 20.08 20.122 20.041 3.68 20.07 20.11 20.022 3.41 20.04 20.079 20.007 3.57 20.06 20.104 20.017 3.86 20.08 20.124 20.037
Male, 18–44 years 4.41 4.43 20.01 20.11 20.082 5.13 20.09 20.178 20.006 4.52 0.00 20.083 20.09 5.67 20.09 20.15 20.031 4.97 20.08 20.175 20.017
Male, 45–65 years 2.79 3.81 20.10 20.149 20.041 3.16 20.06 20.123 20.002 3.02 20.05 20.112 20.017 2.97 20.05 20.122 20.022 3.54 20.09 20.149 20.025
Male, 65 þ years 3.63 4.08 20.07 20.146 20.004 3.75 20.04 20.118 20.042 3.72 20.03 20.102 20.043 3.66 20.02 20.102 20.064 3.85 20.05 20.128 20.028
BMI , ¼ 25
Female 9.43 9.61 0.03 20.003 20.066 9.48 0.02 20.024 20.064 9.59 0.03 20.007 20.067 9.45 20.01 20.045 20.032 9.47 0.02 20.026 20.056
Female, 18–44 years 1.21 1.3 0.02 20.037 20.079 1.22 0.01 20.07 20.089 1.19 0.00 20.064 20.074 1.19 0.01 20.063 20.075 1.21 0.00 20.074 20.079
Female, 45–65 years 6.42 6.47 0.02 20.039 20.071 6.47 0.02 20.047 20.086 6.65 0.03 20.018 20.087 6.43 20.01 20.061 20.046 6.43 0.01 20.054 20.07
Female, 65 þ years 9.19 10.62 0.09 0.019 20.169 9.2 20.01 20.099 20.083 9.75 0.06 20.02 20.142 9.71 20.06 20.141 20.028 9.2 0.01 20.074 20.089
Male 3.66 4.54 0.10 0.024 20.181 3.7 20.02 20.102 20.064 4 0.04 20.018 20.107 4.17 20.07 20.151 20.005 3.9 20.05 20.133 20.031
Male,18–44 years 6.57 10.01 0.21 0.048 20.375 6.87 20.06 20.211 20.091 7.69 0.08 20.04 20.195 8.37 20.11 20.215 20.002 7.44 20.11 20.271 20.057
Male, 45–65 years 4.22 4.38 0.04 20.072 20.158 4.24 0.02 20.13 20.165 4.41 0.04 20.084 20.171 4.27 20.03 20.185 20.128 4.35 20.04 20.177 20.097
Male, 65 þ years 10.31 11.16 0.10 20.041 20.255 10.31 0.00 20.132 20.141 10.55 0.04 20.05 20.126 10.49 20.05 20.182 20.085 10.31 0.00 20.133 20.132
25 , BMI , ¼ 30
Female 9.16 9.16 20.01 20.049 20.038 9.17 20.01 20.061 20.041 9.08 0.00 20.043 20.047 9.08 20.01 20.052 20.04 9.24 20.02 20.069 20.025
Female, 18–44 years 10.3 11.54 0.01 20.021 20.214 11.55 0.11 20.035 20.247 12.76 0.14 0.02 20.251 10.36 20.02 20.136 20.098 11.23 0.083 20.044 20.21
Female, 45–65 years 4.87 5.01 20.02 20.094 20.036 5.12 20.04 20.125 20.037 4.87 20.00 20.063 20.062 4.97 20.02 20.089 20.042 5.31 20.05 20.127 20.023
Female, 65 þ years 5.58 5.58 20.00 20.069 20.063 5.58 0.00 20.068 20.068 5.66 20.02 20.098 20.048 5.66 0.03 20.045 20.103 5.65 20.02 20.08 20.045
Male 3.7 3.71 0.01 20.038 20.055 3.72 0.01 20.043 20.071 3.7 0.02 20.037 20.069 3.67 20.01 20.072 20.053 3.7 20.00 20.06 20.057
Male, 18–44 years 3.09 3.34 0.04 20.064 20.136 3.16 20.02 20.122 20.082 3.43 20.04 20.139 20.068 3.26 0.02 20.12 20.152 3.21 20.03 20.14 20.087
Male, 45–65 years 1.06 1.07 20.01 20.076 20.061 1.12 0.02 20.066 20.109 1.15 0.03 20.058 20.11 1.08 20.01 20.114 20.087 1.07 0.00 20.088 20.096
Male, 65 þ years 5.74 5.74 0.01 20.077 20.087 5.8 0.03 20.08 20.133 5.83 0.03 20.061 20.115 5.76 20.02 20.118 20.087 5.74 0.00 20.1 20.102
BMI . 30
Female 7.21 9.71 20.13 20.179 20.073 8.79 20.11 20.159 20.053 8.37 20.08 20.131 20.029 7.29 20.02 20.072 20.028 8.63 20.09 20.14 20.043
Female, 18–44 years 7.5 14.77 20.18 20.284 20.08 10.2 20.12 20.247 20.001 12.86 20.14 20.236 20.046 7.88 0.04 20.076 20.152 9.7 20.10 20.224 20.02
Female, 45–65 years 5.47 7.16 20.10 20.174 20.02 6.84 20.10 20.183 20.018 7.12 20.10 20.175 20.023 5.47 0.00 20.079 20.082 6.78 20.09 20.165 20.015
Female, 65 þ years 6.8 8.67 20.14 20.236 20.034 7.55 20.08 20.165 20.011 6.81 0.01 20.074 20.088 7.8 20.09 20.164 20.006 7.5 20.07 20.147 20.014
Male 6.75 7.19 20.06 20.127 20.016 6.82 20.02 20.105 20.056 6.77 20.01 20.096 20.076 6.9 20.04 20.125 20.045 6.85 20.03 20.102 20.046
Male, 18–44 years 19.83 19.86 0.02 20.174 20.209 21.07 20.11 20.315 20.088 21.63 0.11 20.075 20.29 26.02 20.17 20.277 20.065 19.83 20.00 20.208 20.204
Male, 45–65 years 8.99 9.29 20.04 20.126 20.044 8.99 0.00 20.096 20.106 9.32 20.01 20.13 20.113 9.33 0.02 20.11 20.14 9.09 20.03 20.118 20.067
Male, 65 þ years 4.99 6.09 20.11 20.266 20.054 5.08 20.03 20.203 20.145 5.97 20.01 20.261 20.074 5.58 0.10 20.17 20.364 5.05 20.02 20.171 20.128
aEstimated association of IGF-I SDS and diabetes, liver diseases, kidney diseases, CAD, cancer, hypertension, dyslipidemia, fibrate intake, HRT, and age; bestimated association of IGF-I SDS and nutri-
tional parameters, diabetes, liver diseases, kidney diseases, CAD, cancer, hypertension, dyslipidemia, fibrate intake, HRT, and age.
CI, confidence intervals; CAD, coronary artery disease; HRT, hormone replacement therapy.
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When analyzing subgroups with normal and
underweight (BMI # 25 kg/m2), overweight (BMI
25–30 kg/m2), and obese subjects (BMI . 30 kg/m2),
we found diverging results. In normal and underweight
subjects we found a positive association between IGF-I
SDS and BMI in men, but not in women. Subgroup ana-
lysis revealed that this effect was most pronounced in
men aged 18–44 years, but it was not significant in
men of other age groups, whereas a significant positive
association was found in women aged 65 years or
older, but not in women of other age groups. There
were no significant associations between IGF-I and BMI
in overweight individuals. Obese women showed a
marked negative correlation that was most pronounced
in women aged 18–44 years. In obese men, BMI was not
significantly associated with IGF-I SDS but in the young
age group, WHR was significantly negatively associated
with IGF-I SDS. In most age subgroups, BMI added
most to the explained variance compared with other
anthropometric parameters. Only in men aged 18–44
years did the WHR prove to have the strongest associ-
ation with IGF-I SDS.
Discussion
To our knowledge, this is the largest study to date asses-
sing the association of IGF-I with nutritional status. In
addition, age-dependent IGF-I SDS calculated from the
largest published reference sample for IGF-I measure-
ment (29) were used instead of IGF-I levels to analyze
associations between IGF-I and various nutritional par-
ameters. By this approach, the confounding effects of
the age-dependent decline in IGF-I levels could be
excluded. The IGF-I SDS mean in our sample was
slightly higher than zero and there was a less steep
age-related decline than in Brabant et al. (29). The
reason for these differences is unclear. Possibly, differ-
ences in morbidities might have played a role. Due to
this difference, we additionally adjusted for age in our
regression analyses.
Our study clearly established opposite associations of
nutritional parameters with IGF-I SDS in normal
weight and obese subjects.
It is known that IGF-I levels are decreased in under-
weight individuals (15 –18) and this has been attribu-
ted to GH resistance. The present data extend this
observation by showing a continuous increase in
IGF-I SDS throughout the normal weight range in
both sexes and even further in women. In men with a
BMI # 25 kg/m2, we also found a positive correlation
after controlling for possibly confounding health con-
ditions and medications. This observation might indi-
cate that GH sensitivity is not only reduced in severe
underweight states, but also may steadily increase
within the normal BMI range.
In obese subjects, on the other hand, mean IGF-I SDS
decreased with BMI. This confirms the results of some
(20 –22) but not all (23 –25) previous studies. In our
subgroup of obese subjects, an increase of one S.D. of
BMI led to a mean decrease of 0.13 and 0.06 IGF-I
SDS in women and men respectively. In the literature,
a more pronounced impairment of GH secretion in
obesity is described, with a reduction of GH production
to a quarter of that in normal weight subjects (30).
Based on these results on GH secretion in obesity, our
results suggest that the reduction in GH secretion is
only partially translated into reduced IGF-I secretion.
The reason for this is unclear, but again, an increase
in GH sensitivity has been discussed (25). In a popu-
lation-based study with 400 subjects, a negative corre-
lation of IGF-I with BMI was found that disappeared
after adjustment for age (26). We found significant
effects of BMI, even after adjustment for age and
other health conditions. Possibly, the larger sample
number of our study has revealed these associations.
BMI adds about 1% to the explained variance of IGF-I
SDS in the total population and up to 7% in obese sub-
groups. Overall, different health conditions only render
about 3–8% of explained variance in the total group
and up to 20% in obese subgroups. These results
show that a major part of IGF-I SDS variance still
needs to be explained by other factors not assessed in
this study, such as genetics or others.
In some studies, a strong negative correlation of visc-
eral fat mass with IGF-I has been found indicating that
visceral fat rather than overall body mass determines
IGF-I levels (27, 28). We have studied several anthropo-
metric indicators of visceral fat accumulation including
the WC and the WTR, which have been shown to cor-
relate with intra-abdominal fat (32). Surprisingly, it
was the BMI rather than these parameters that added
most to explained variance of IGF-I SDS in our total
population. However, in the subgroup of young men,
the WHR had a better association with IGF-I than
with BMI. Since in the study of Kunitomi et al. (28),
younger and middle-aged obese men were also investi-
gated, differences between patient populations might be
one important explanation for the differences between
earlier reports and our study. Moreover, an age-depen-
dent decline in IGF-I, excluded by our approach to the
analysis of IGF-I SDS, might have further confounded
the findings of previous studies.
The influence of BMI on IGF-I levels is of considerable
relevance for studies investigating the association
between IGF-I and various disease states. So far, only a
few of these studies have adjusted their IGF-I values to
BMI. Laughlin et al. (11) have, in a prospective study,
investigated the association between IGF-I and cardio-
vascular risk in a large cohort of older adults from the
Rancho Bernardo Study. They found a significant
increase in both cardiovascular and all-cause mortality
for every unadjusted IGF-I decrease of 40mg/l (1 SD),
which was still significant after adjusting for age. How-
ever, when adjusted for age, sex, BMI and prevalent dis-
ease, the difference was no longer significant.
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In conclusion, our results indicate that BMI is a
slightly better predictor of IGF-I than other anthropo-
metric indicators of nutritional state, and they provide
data on the magnitude of this influence in relation to
age, BMI and sex. There are opposite associations of
BMI to IGF-I SDS in normal weight and in obese indi-
viduals. The associations are particularly strong in
obese subjects and, in addition, there are sex differences
in some subgroups. The data stress the importance of
clearly defining subject populations when analyzing
the associations of hormonal parameters with nutrition
and body composition. These interactions must be
taken into account when studying the associations of
IGF-I and health conditions that are related to obesity,
such as cardiovascular diseases or cancer. Moreover,
IGF-I is used to monitor therapy in acromegaly (4)
and GH deficiency (1, 3, 33). The association of BMI
with IGF-I should be taken into account when titrating
therapy in these patients and, possibly, age- and BMI-
dependent reference values should be considered in
the future.
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